HCM
HCM clinical trials: HUTCHMED (China) Ltd
Every trial on ClinicalTrials.gov where HUTCHMED (China) Ltd is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 53
- Trials linked
- 51
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
HCM on the catalyst calendar · HCM registry changes
- Primary completion Apr 30, 2028Sponsor estimatePhase 3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed · Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2032Sponsor estimatePhase 3NCT07912398HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 MutationsHutchmed · Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNot yet recruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 28, 2026ActualPhase 2/Phase 3NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Hutchmed · Advanced Renal Cell CarcinomaCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2029Sponsor estimatePhase 1/Phase 2NCT07718581HMPL-A830 in Solid TumorsHutchmed · Solid Tumor, AdultRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2026ActualPhase 2NCT06601504Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed · Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2026ActualPhase 1NCT07643272A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 CapsulesHutchmed · Healthy ParticipantsCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 1/Phase 2NCT07396584HMPL-A580 in Participants With Advanced or Metastatic Solid TumorHutchmed · Solid Tumors, AdultRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2028Sponsor estimatePhase 1/Phase 2NCT07228247A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid TumorsHutchmed · Solid Tumors, AdultRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2028Sponsor estimatePhase 3NCT05009836Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCHutchmed · Non-small Cell Lung CancerActive, not recruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2028Sponsor estimatePhase 2/Phase 3NCT06361888A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in...Hutchmed · Metastatic Pancreatic CancerRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2025ActualPhase 1NCT07697157The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate TabletsHutchmed · Health, SubjectiveCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 14, 2025ActualPhase 1NCT07644442Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmed · Mass Balance StudyCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 25, 2025ActualPhase 2/Phase 3NCT05535933HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaHutchmed · Warm Antibody Autoimmune Hemolytic AnemiaActive, not recruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 16, 2025ActualPhase 3NCT05029635Phase III Study on HMPL-523 for Treatment of ITPHutchmed · Primary Immune Thrombocytopenia (ITP)CompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2025ActualPhase 1NCT04762602A Study of HMPL-306 in Advanced Solid Tumors With IDH MutationsHutchmed · Isocitrate Dehydrogenase Gene MutationTerminatedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2026ActualPhase 1NCT07348133Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate TabletsHutchmed · HealthyCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 28, 2025ActualPhase 1NCT07331194Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in HumansHutchmed · HealthyCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2025ActualPhase 1NCT03779113An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaHutchmed · Non Hodgkin LymphomaTerminatedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2025ActualPhase 1NCT04764474A Study of HMPL-306 in Advanced Hematological Malignancies With mIDHHutchmed · Isocitrate Dehydrogenase Gene MutationTerminatedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 2/Phase 3NCT04353375HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaHutchmed · Advanced Intrahepatic CholangiocarcinomaRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2027Sponsor estimatePhase 1NCT06387082A Clinical Study of HMPL-506 in Patients With Hematological MalignanciesHutchmed · Hematological MalignanciesRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2026Sponsor estimatePhase 1NCT06291415The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)Hutchmed · Immune ThrombocytopeniaWithdrawnHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 6, 2024ActualPhase 1/Phase 2NCT05077384Open-label Study of Surufatinib in Japanese PatientsHutchmed · Neuroendocrine TumorsCompletedHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 3NCT06387069A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaHutchmed · Acute Myeloid LeukemiaRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07025018Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 MutationsHutchmed · Gliomas Harboring IDH1 and/or IDH2 MutationsRecruitingHCMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 28 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner